Gallant has announced $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for veterinary medicine, targeting Feline Chronic Gingivostomatitis with potential approval by early 2026. Early studies indicate positive results in dogs with arthritis, while mixed results were observed for kidney disease treatments in cats. Gallant's innovative approach utilizes ready-to-use cells from donor animals, bypassing traditional harvesting methods. Led by Linda Black, following founder Aaron Hirschhorn’s passing, Gallant has raised a total of $44 million from investors, including Digitalis Ventures and NovaQuest Capital Management.
Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine, targeting Feline Chronic Gingivostomatitis by 2026.
The field has shown early results in dogs with arthritis, showing improvements in pain and mobility, though results for kidney disease in cats have been mixed.
Gallant's approach uses ready-to-use cells from donor animals, contrasting with current methods that require harvesting cells from the patient or matching tissue donors.
Gallant's funding was led by Digitalis Ventures, with participation from NovaQuest, who previously invested in the first FDA-approved human stem cell therapy.
Collection
[
|
...
]